Ask AI

Next-Generation CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: The Science, Strategy, and Signals to Inform Clinical Readiness

Deepen your understanding of the biologic rationale for novel CDH6-targeting ADCs in ovarian cancer based on current and emerging clinical trial data through a podcast, certified text module with accompanying downloadable slides, and an expert-written ClinicalThought commentary.

Share

Program Content

Activities

CDH6 ADCs
CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: November 05, 2025

Activities

CDH6 Ovarian Cancer
Next-Generation CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: The Science, Strategy, and Signals to Inform Clinical Readiness
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: January 26, 2026

Expires: July 25, 2026

Activities

CDH6 ADCs Ovarian
The Latest Data on CDH6-Targeted Treatment for Ovarian Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 26, 2026

Activities

CDH6 ADCs Ovarian Cancer
Expert Insight Into CDH6-Targeting Antibody–Drug Conjugates for Ovarian Cancer
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 03, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

Supporters

Supported by educational grants from Daiichi Sankyo, Inc and Merck Sharp & Dohme, LLC

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC